Navigation Links
New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
Date:11/7/2007

ORLANDO, Fla., Nov. 7 /PRNewswire-USNewswire/ -- Results from the latest generation of the long-term Framingham Heart Study were presented today here at the American Heart Association's Scientific Sessions. The data indicates a strong relationship between decreased microvascular function and cardiovascular risk.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071107/DC06799 )

Itamar Medical's ENDO-Pat device was the diagnostic tool used in this phase of the Framingham study, which found a link between endothelial dysfunction and cardiovascular risk factors including cholesterol, blood pressure and being overweight. In light of this latest scientific confirmation of PAT technology, Itamar Medical will now promote widespread clinical use of this approach for the prevention of cardiovascular disease.

Based on several new studies released here, combined with earlier numerous successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment.

The Endo-PAT, developed by Itamar Medical, is the only FDA approved non-invasive device that reliably detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer, which is the inner tissue lining of the blood vessels and is emerging as a key precursor for the development of atherosclerosis -- a major component in cardiac disease, the nation's number one killer.

The non-invasive Endo-PAT device, based on PAT technology, measures subtle but significant vaso-motion changes through a small thimble-like probe placed over a person's index finger. Tests administered with the Endo-PAT provide clinicians and researchers an effective tool for the detection of endothelial dysfunction. Early detection has the potential to reduce the medical and cost burden of cardiovascular disease. Valuable diagnostic information can be obtained from the Endo-PAT at a fraction of the cost of other established approaches which can only be administered by a skilled technician and even then are too operator dependent.

In addition to the data from the Framingham Heart Study, that showed in a large population base study an association between the Endo-PAT results and several risk factors, three other oral presentations from Britain and Sweden showed the relevancy of endothelial function assessment with the Endo-PAT in other conditions in children and adults.

About Itamar Medical

Itamar Medical Ltd., established in 1997, is a public (TASE: ITMR) medical technology company that developed the proprietary PAT(TM) (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. For more information, visit http://www.itamar-medical.com


'/>"/>
SOURCE Itamar Medical
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):